114694-12-1

Basic information

• Product Name: (2s)-2-((3aS,7aR,E)-4-((E)-2-((3S,5R)-3,5-bis((tert-butyldimethylsilyl)oxy)-2-methylenecyclohexylidene)ethylidene)-7a-methyloctahydro-1H-inden-1-yl)propanal
• CAS NO: 114694-12-1
• Molecular Formula: C34H62O3Si2
• Molecular Weight: 575.035
• Mol File: 114694-12-1.mol

Chemical Properties

• CAS DataBase Reference: (2s)-2-((3aS,7aR,E)-4-((E)-2-((3S,5R)-3,5-bis((tert-butyldimethylsilyl)oxy)-2-methylenecyclohexylidene)ethylidene)-7a-methyloctahydro-1H-inden-1-yl)propanal(CAS DataBase Reference)
• NIST Chemistry Reference: (2s)-2-((3aS,7aR,E)-4-((E)-2-((3S,5R)-3,5-bis((tert-butyldimethylsilyl)oxy)-2-methylenecyclohexylidene)ethylidene)-7a-methyloctahydro-1H-inden-1-yl)propanal(114694-12-1)
• EPA Substance Registry System: (2s)-2-((3aS,7aR,E)-4-((E)-2-((3S,5R)-3,5-bis((tert-butyldimethylsilyl)oxy)-2-methylenecyclohexylidene)ethylidene)-7a-methyloctahydro-1H-inden-1-yl)propanal(114694-12-1)

Safety Data

• Hazardous Substances Data: 114694-12-1(Hazardous Substances Data)

Upstream product

• 114694-11-0 (5Z,7E)-(1S,3R,20S)-1,3-bis<(tert-butyldimethylsilyl)oxy>-9,10-seco-5,7,10(19)-pregnatriene-20-carboxylic acid methyl ester 
• 566-77-8 hydroxybisnorcholenic acid 
• 10527-79-4 methyl 3β-hydroxy-23-bisnorchol-5-en-22-oate 
• 99518-39-5 3β-hydroxy-22,23-dinor-5,7-choladienic acid methyl ester 
• 1474-14-2 3β-acetoxybisnor-5-cholenic acid 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 97903-26-9 (7E)-(3R,5R,6R,20S)-6-methoxy-3,5-cyclo-9,10-seco-7,10⁽¹⁹⁾-pregnadiene-20-carboxylic acid methyl ester 
• 114694-15-4 (S)-2-{(1R,3aS,7aR)-4-[(R)-2-((1R,3S,5R)-3-Hydroxy-2-methylene-bicyclo[3.1.0]hex-1-yl)-2-methoxy-eth-(E)-ylidene]-7a-methyl-octahydro-inden-1-yl}-propionic acid methyl ester 
• 114694-16-5 (5Z,7E)-(1S,3R,20S)-1-hydroxy-3-acetoxy-9,10-seco-5,7,10⁽¹⁹⁾-pregnatriene-20-carboxylic acid methyl ester 
• 112924-91-1 (5Z,7E)-(1S,3R,20S)-1,3-bis<(tert-butyldimethylsilyl)oxy>-9,10-seco-22,23-dinor-5,7,10(19)-cholatrien-24-al 
• 114694-17-6 (S)-2-{(1R,3aS,7aR)-4-[2-[(3S,5R)-3,5-Dihydroxy-2-methylene-cyclohex-(Z)-ylidene]-eth-(E)-ylidene]-7a-methyl-octahydro-inden-1-yl}-propionic acid methyl ester 
• 97903-25-8 (S)-2-{(1R,3aS,7aR)-7a-Methyl-4-[2-[(S)-2-methylene-5-(toluene-4-sulfonyloxy)-cyclohex-(Z)-ylidene]-eth-(E)-ylidene]-octahydro-inden-1-yl}-propionic acid methyl ester 
• 69454-87-1 (3β,20S)-3-<(tert-butyldimethylsilyl)oxy>pregn-5-ene-20-carboxylic acidmethyl ester 
• 97903-24-7 (5Z,7E)-(3S,20S)-3-hydroxy-9,10-seco-5,7,10⁽¹⁹⁾pregnatriene-20-carboxylic acid methyl ester 

Downstream Products

• 137832-47-4 ((S)-2-{(R)-4-[2-[(3S,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(E)-ylidene]-eth-(E)-ylidene]-7a-methyl-octahydro-inden-1-yl}-propoxy)-acetic acid tert-butyl ester 
• 116391-23-2 (S)-2-{(1R,7aR)-4-[2-[(S)-5-Hydroxy-2-methylene-cyclohex-(Z)-ylidene]-eth-(E)-ylidene]-7a-methyl-octahydro-inden-1-yl}-propionaldehyde 
• 112924-91-1 (5Z,7E)-(1S,3R,20S)-1,3-bis<(tert-butyldimethylsilyl)oxy>-9,10-seco-22,23-dinor-5,7,10(19)-cholatrien-24-al 
• 114694-13-2 (5Z,7E)-(1S,3R,20S)-1,3-bis<(tert-butyldimethylsilyl)oxy>-9,10-seco-22,23-dinor-5,7,10(19)-cholatrienol 22-p-toluenesulfonate 
• 114694-09-6 PRI-1890 
• 114694-10-9 26,27-trimethylene-1,25-dihydroxyvitamin D₃ 
• 114694-28-9 (1R,3aS,7aR)-4-[2-[(3S,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(Z)-ylidene]-eth-(E)-ylidene]-7a-methyl-1-[(R)-1-methyl-4-(1-triethylsilanyloxy-cyclopentyl)-butyl]-octahydro-indene 
• 114694-21-2 (1R,3aS,7aR)-4-[2-[(3S,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(Z)-ylidene]-eth-(E)-ylidene]-1-((R)-1,7-dimethyl-7-triethylsilanyloxy-octyl)-7a-methyl-octahydro-indene 
• 114694-26-7 (1R,3aS,7aR)-1-[(R)-3-Benzenesulfonyl-1-methyl-4-(1-triethylsilanyloxy-cyclopentyl)-butyl]-4-[2-[(3S,5R)-3,5-bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(Z)-ylidene]-eth-(E)-ylidene]-7a-methyl-octahydro-indene 
• 114694-33-6 (2S,5S)-4-Benzenesulfonyl-2-{(1R,3aS,7aR)-4-[2-[(3S,5R)-3,5-bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(Z)-ylidene]-eth-(E)-ylidene]-7a-methyl-octahydro-inden-1-yl}-5,6-dimethyl-6-(tetrahydro-furan-2-yloxy)-heptan-3-ol 
• 114760-82-6 (1R,3aS,7aR)-1-((1R,3S)-3-Benzenesulfonyl-1,7-dimethyl-7-triethylsilanyloxy-octyl)-4-[2-[(3S,5R)-3,5-bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(Z)-ylidene]-eth-(E)-ylidene]-7a-methyl-octahydro-indene 
• 114694-20-1 (1R,3aS,7aR)-1-((1R,3R)-3-Benzenesulfonyl-1,7-dimethyl-7-triethylsilanyloxy-octyl)-4-[2-[(3S,5R)-3,5-bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(Z)-ylidene]-eth-(E)-ylidene]-7a-methyl-octahydro-indene 
• 95783-08-7 (24R)-1α,25-dihydroxyvitamin D₂ 
• 114694-35-8 (E)-(3R,6R)-6-{(1R,3aS,7aR)-4-[2-[(3S,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(Z)-ylidene]-eth-(E)-ylidene]-7a-methyl-octahydro-inden-1-yl}-2,3-dimethyl-hept-4-en-2-ol 

Relevant articles and documents

VITAMIN D3 LACTONE DERIVATIVE

A compound represented by the following Formula (1) that is effective for the treatment of Paget's disease of bone or hypercalcemia or a medically acceptable solvate thereof; [wherein R1 refers to hydrogen atom, C1-C6 alky

VITAMIN D3 DERIVATIVES AND REMEDIES USING THE SAME

A vitamin D3 derivative expressed by the following general formula (1) [wherein, R is a hydrogen atom or a methyl group, and A is a single bond, -CH2-, -CH=CH-, -CH2-CH=CH-, -CH=CH-CH=CH-, -C=C- or -CH2-C≡C-; an

Synthesis and antiproliferative activity of side-chain unsaturated and homologated analogs of 1,25-dihydroxyvitamin D(2). (24E)-(1S)-24-Dehydro-24a-homo-1,25-dihydroxyergocalciferol and congeners.

A series of analogs of 1,25-dihydroxyergocalciferol (1-4) was synthesized and screened for their antiproliferative activity in vitro. The structure of new analogs was designed based on biological activity of the previously obtained side-chain modified analogs of vitamin D(2) and D(3). The analogs were obtained by the Julia olefination of C(22)-vitamin D sulfone 11 with side-chain aldehyde 15. The analogs were tested for their antiproliferative activity against the cells of human breast cancer lines T47D and MCF7 as well as human and mouse leukemia lines, HL-60 and WEHI-3, respectively. Analog 2 (PRI-1907) showed the strongest antiproliferative activity out of the present series of analogs of 1,25-dihydroxyvitamin D(2) with the mono homologated and double unsaturated side chain. The activity of 2 was 3-150 times stronger, depending on the cell line, than that of 1,25-dihydroxycholecalciferol (calcitriol), used as standard. Copyright 2002 Elsevier Science Inc.

Novel Convergent Synthesis of Side-Chain-Modified Analogues of 1α,25-Dihydroxycholecalciferol and 1α,25-Dihydroxyergocalciferol

A novel synthetic strategy for the preparation of side-chain-modified analogues of 1α,25-dihydroxycholecalciferol and 1α,25-dihydroxyergocalciferol was developed as a part of the extensive synthetic search for vitamin D analogues of potential anticancer a